Company Encyclopedia
View More
name
Liquidia Tech
LQDA.US
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD.
4.514 T
LQDA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking55/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-187.21%E
    • Profit Margin-179.28%E
    • Gross Margin94.16%A
  • Growth ScoreB
    • Revenue YoY343.41%A
    • Net Profit YoY-5.85%C
    • Total Assets YoY9.13%B
    • Net Assets YoY-80.05%E
  • Cash ScoreB
    • Cash Flow Margin-55.78%D
    • OCF YoY343.41%A
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreE
    • Gearing Ratio92.01%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Liquidia (NASDAQ:LQDA) Hits New 12-Month High - Here's What Happened

    Liquidia Corporation (NASDAQ:LQDA) reached a new 52-week high, trading at $33.42. Analysts have given the stock a consensus rating of "Moderate Buy" with a price target of $38.56. The company reported a significant revenue increase, beating earnings estimates. Insider trading activity includes sales by CFO Michael Kaseta and Director Raman Singh. Institutional investors have modified their holdings, with 64.54% of the stock owned by them.

    Market Beat·
    US
    LQDA
    +0.53%
    Market Beat·
    US
    LQDA
    +0.53%

    Officer Adair Acquires 870 Of Liquidia Corp [LQDA]

    Officer Jason Adair of Liquidia Corp [LQDA] filed a Form 4 on December 2, 2025, disclosing changes in ownership. He exercised 1,563 shares and surrendered 693 shares at $32.19 each, ending with 175,868 direct holdings. The surrender was to cover option exercise costs and tax liabilities, executed under a prearranged trading plan (10b5-1).

    Reuters·
    US
    LQDA
    +0.53%
    Reuters·
    US
    LQDA
    +0.53%

    A Fresh Look at Liquidia (LQDA) Valuation After Strong Share Price Gains

    Liquidia (LQDA) shares have surged 33.5% in the past month, with a year-to-date increase of 146.9%. Despite strong gains, its price-to-sales ratio of 37.5x suggests overvaluation compared to industry norms. However, a discounted cash flow model estimates its fair value at $196.66, indicating potential undervaluation. The market's high expectations may shift if growth targets aren't met. Simply Wall St provides analysis but not financial advice.

    Simplywall·
    US
    LQDA
    +0.53%
    Simplywall·
    US
    LQDA
    +0.53%

    Liquidia Chief Accounting Officer Dana Boyle Reports Sale of Common Shares

    Dana Boyle, Chief Accounting Officer of Liquidia Corporation, reported the sale of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. Liquidia Corporation published the original content via EDGAR on November 12, 2025.

    Reuters·
    US
    LQDA
    +0.53%
    Reuters·
    US
    LQDA
    +0.53%

    Chief Medical Officer Of Liquidia Sold 60% Of Their Shares

    Liquidia Corporation's Chief Medical Officer, Rajeev Saggar, sold 60% of his shares, netting approximately $1.9 million at an average price of $27.00. This significant sale raises concerns among shareholders, especially as insiders have not purchased shares in the past year. Liquidia insiders own 10% of the company, valued at about $228 million. While insider ownership is generally positive, the lack of recent buying and the recent selling activity may indicate potential risks for the company.

    Simplywall·
    US
    LQDA
    +0.53%
    Simplywall·
    US
    LQDA
    +0.53%
    © 2025 Longbridge｜Disclaimer